A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities
收藏DataCite Commons2025-11-18 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011957/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
提供机构：
Vivli
创建时间：
2025-11-17
